At a glance
ClinicalIndex Comparison Record- ✓Diagnosed with HFpEF within the past 6 months
- ✓NYHA Classification II-III (moderate to severe symptoms)
- ✓Left ventricular ejection fraction ≥50% on echocardiogram
- ✓Reliable phone contact and own transportation to study site
- ✕Acute coronary syndrome within past 12 weeks
- ✕Significant valvular heart disease
- ✕Severe cardiac fibrosis (galectin-3 level >26 ng/ml)
- ✕Constrictive pericardium or hypertrophic/infiltrative cardiomyopathy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Reducing Symptom Burden in Patients With Heart Failure With Preserved Ejection Fraction Using Ubiquinol and/or D-ribose
In Brief
A Phase 2 clinical trial evaluating CoQ10, D-Ribose Oral Powder, and 2 other interventions for Heart Failure, Diastolic. Completed, enrolled 216 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the clinical benefits of CoQ10 and D-ribose taken by patients who have diastolic heart failure, or heart failure with preserved ejection fraction (HFpEF).
Study Details
Timeline
Interventions
Participants will take 300 mg capsules two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.
Participants will mix 15 grams D-Ribose powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.
Participants will take matched placebo pills that are 300 mg capsules, two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.
Participants will mix 15 grams placebo powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.